Cargando…

Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial)

Grade 3 (G3, poorly differentiated) is an important treatment-decision factor in stage II colon cancer, but no unified diagnostic criteria are established. According to previous studies, an intratumoural poorly differentiated area with no glandular formation (POR) that fills the microscopic field of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueno, Hideki, Ishiguro, Megumi, Nakatani, Eiji, Ishikawa, Toshiaki, Uetake, Hiroyuki, Matsui, Shigeyuki, Teramukai, Satoshi, Murotani, Kenta, Ajioka, Yoichi, Shimazaki, Hideyuki, Maeda, Atsuyuki, Takuma, Kunio, Yoshida, Takefumi, Kambara, Takeshi, Matsuda, Keiji, Takagane, Akinori, Tomita, Naohiro, Sugihara, Kenichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690643/
https://www.ncbi.nlm.nih.gov/pubmed/32868525
http://dx.doi.org/10.1097/PAS.0000000000001570
_version_ 1783614114842542080
author Ueno, Hideki
Ishiguro, Megumi
Nakatani, Eiji
Ishikawa, Toshiaki
Uetake, Hiroyuki
Matsui, Shigeyuki
Teramukai, Satoshi
Murotani, Kenta
Ajioka, Yoichi
Shimazaki, Hideyuki
Maeda, Atsuyuki
Takuma, Kunio
Yoshida, Takefumi
Kambara, Takeshi
Matsuda, Keiji
Takagane, Akinori
Tomita, Naohiro
Sugihara, Kenichi
author_facet Ueno, Hideki
Ishiguro, Megumi
Nakatani, Eiji
Ishikawa, Toshiaki
Uetake, Hiroyuki
Matsui, Shigeyuki
Teramukai, Satoshi
Murotani, Kenta
Ajioka, Yoichi
Shimazaki, Hideyuki
Maeda, Atsuyuki
Takuma, Kunio
Yoshida, Takefumi
Kambara, Takeshi
Matsuda, Keiji
Takagane, Akinori
Tomita, Naohiro
Sugihara, Kenichi
author_sort Ueno, Hideki
collection PubMed
description Grade 3 (G3, poorly differentiated) is an important treatment-decision factor in stage II colon cancer, but no unified diagnostic criteria are established. According to previous studies, an intratumoural poorly differentiated area with no glandular formation (POR) that fills the microscopic field of a ×40 objective lens was an essential factor that defined G3. We aimed to prospectively validate this in a randomized controlled study of adjuvant chemotherapy (SACURA trial). We enrolled 991 patients with stage II colon cancer. POR was graded according to the ×40 objective lens rule and the intensity of poorly differentiated clusters (Grade(POR)), and its prognostic power was compared with that of the conventional tumor grade on the basis of predominant histology rule (Grade(conv)). According to Grade(POR), 313, 526, and 152 tumors were classified as G1(POR), G2(POR), and G3(POR), respectively, and the 5-year relapse-free survival (RFS) rates were 91.1%, 82.9%, and 74.7%, respectively (P<0.0001). When G3(POR) and G3(conv) were alternatively added to the prognostic model consisting of 8 conventional factors, only G3(POR) was a significant factor for RFS (P=0.040, Wald test). The adverse impact of G3(POR) on RFS was greater in the microsatellite stable/microsatellite instability–low subset than that in the full analysis set. In the microsatellite stable/microsatellite instability–low subset, the 5-year RFS rate of patients with G3(POR) tumors in the chemotherapy group achieved greater improvement (9.1%) than the surgery-alone group. The least differentiation policy with the ×40 objective lens rule may be highlighted as the diagnostic criterion for G3 because of its validated prognostic value.
format Online
Article
Text
id pubmed-7690643
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-76906432020-12-01 Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial) Ueno, Hideki Ishiguro, Megumi Nakatani, Eiji Ishikawa, Toshiaki Uetake, Hiroyuki Matsui, Shigeyuki Teramukai, Satoshi Murotani, Kenta Ajioka, Yoichi Shimazaki, Hideyuki Maeda, Atsuyuki Takuma, Kunio Yoshida, Takefumi Kambara, Takeshi Matsuda, Keiji Takagane, Akinori Tomita, Naohiro Sugihara, Kenichi Am J Surg Pathol Original Articles Grade 3 (G3, poorly differentiated) is an important treatment-decision factor in stage II colon cancer, but no unified diagnostic criteria are established. According to previous studies, an intratumoural poorly differentiated area with no glandular formation (POR) that fills the microscopic field of a ×40 objective lens was an essential factor that defined G3. We aimed to prospectively validate this in a randomized controlled study of adjuvant chemotherapy (SACURA trial). We enrolled 991 patients with stage II colon cancer. POR was graded according to the ×40 objective lens rule and the intensity of poorly differentiated clusters (Grade(POR)), and its prognostic power was compared with that of the conventional tumor grade on the basis of predominant histology rule (Grade(conv)). According to Grade(POR), 313, 526, and 152 tumors were classified as G1(POR), G2(POR), and G3(POR), respectively, and the 5-year relapse-free survival (RFS) rates were 91.1%, 82.9%, and 74.7%, respectively (P<0.0001). When G3(POR) and G3(conv) were alternatively added to the prognostic model consisting of 8 conventional factors, only G3(POR) was a significant factor for RFS (P=0.040, Wald test). The adverse impact of G3(POR) on RFS was greater in the microsatellite stable/microsatellite instability–low subset than that in the full analysis set. In the microsatellite stable/microsatellite instability–low subset, the 5-year RFS rate of patients with G3(POR) tumors in the chemotherapy group achieved greater improvement (9.1%) than the surgery-alone group. The least differentiation policy with the ×40 objective lens rule may be highlighted as the diagnostic criterion for G3 because of its validated prognostic value. Lippincott Williams & Wilkins 2020-12 2020-08-28 /pmc/articles/PMC7690643/ /pubmed/32868525 http://dx.doi.org/10.1097/PAS.0000000000001570 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Original Articles
Ueno, Hideki
Ishiguro, Megumi
Nakatani, Eiji
Ishikawa, Toshiaki
Uetake, Hiroyuki
Matsui, Shigeyuki
Teramukai, Satoshi
Murotani, Kenta
Ajioka, Yoichi
Shimazaki, Hideyuki
Maeda, Atsuyuki
Takuma, Kunio
Yoshida, Takefumi
Kambara, Takeshi
Matsuda, Keiji
Takagane, Akinori
Tomita, Naohiro
Sugihara, Kenichi
Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial)
title Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial)
title_full Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial)
title_fullStr Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial)
title_full_unstemmed Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial)
title_short Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial)
title_sort optimal criteria for g3 (poorly differentiated) stage ii colon cancer: prospective validation in a randomized controlled study (sacura trial)
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690643/
https://www.ncbi.nlm.nih.gov/pubmed/32868525
http://dx.doi.org/10.1097/PAS.0000000000001570
work_keys_str_mv AT uenohideki optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial
AT ishiguromegumi optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial
AT nakatanieiji optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial
AT ishikawatoshiaki optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial
AT uetakehiroyuki optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial
AT matsuishigeyuki optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial
AT teramukaisatoshi optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial
AT murotanikenta optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial
AT ajiokayoichi optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial
AT shimazakihideyuki optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial
AT maedaatsuyuki optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial
AT takumakunio optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial
AT yoshidatakefumi optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial
AT kambaratakeshi optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial
AT matsudakeiji optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial
AT takaganeakinori optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial
AT tomitanaohiro optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial
AT sugiharakenichi optimalcriteriaforg3poorlydifferentiatedstageiicoloncancerprospectivevalidationinarandomizedcontrolledstudysacuratrial